About Araclon
Araclon is a company based in Zaragoza (Spain) founded in 2004 was acquired by Grifols in March 2012. Araclon has raised $11.16 million across 1 funding round from investors including Grifols and Viamed Salud. Araclon offers products and services including ABtest Service, ABtest-IA, ABtest-MS, and ABvac40. Araclon operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Zaragoza, Spain
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Araclon Biotech, S.L.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Araclon
Araclon offers a comprehensive portfolio of products and services, including ABtest Service, ABtest-IA, ABtest-MS, and ABvac40.
Service for early detection of amyloid peptides in plasma samples
Determines total and free Aβ40 and Aβ42 in plasma
Joint determination of Aβ1-40 and Aβ1-42 via mass spectrometry
Active immunotherapy against Aβ40 for Alzheimer's treatment
Funding Insights of Araclon
Araclon has successfully raised a total of $11.16M through 1 strategic funding round. The most recent funding activity was a Series A round of $11.16 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Araclon
Araclon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Grifols and Viamed Salud.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Hospital and healthcare services are delivered with advanced medical technology.
|
Locked | Locked | Locked | |
|
Plasma-derived therapies are developed to treat multiple diseases.
|
Locked | Locked | Locked |
Investor details for Araclon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Araclon
Investment portfolio details for Araclon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Araclon
Detailed financials for Araclon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Araclon Comparisons
Peer comparison for Araclon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Araclon
Araclon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| Locked | Locked | Locked |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
Detailed competitors of Araclon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Araclon
Complete news archive for Araclon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Araclon
Araclon was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Araclon is headquartered in Zaragoza, Spain. It is registered at Zaragoza, Aragon, Spain.
Araclon is a funded company, having raised a total of $11.16M across 1 funding round to date.
Araclon Biotech, a spin-off from the University of Zaragoza is dedicated to the research and development of therapies and diagnostic methods for neurodegenerative disorders with the initial focus on Alzheimers disease (AD). It has developed and patented a treatment called ABVac which based on an active immunotherapy (vaccine) for amyloid beta peptides 40 and 42. It has also developed ABtest kit for the early detection of AD by identifying the beta-amyloid 40 and 42 peptides in blood. It is also working on developing a diagnostic test and therapy for Parkinsons disease. In March 2012, Grifols acquired 51 of the capital of Araclon Biotech and since then Araclon is working as its subsidiary.
Araclon's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Araclon offers ABtest Service, ABtest-IA, ABtest-MS, and ABvac40.
Araclon has 2 investors. Key investors include Grifols, and Viamed Salud.